Paradromics Implants Brain Chip in First Patient: Direct Rival to Neuralink

What Happened?

Paradromics, a neurotechnology company based in Austin, Texas, announced the successful implantation of its Connexus brain-computer interface (BCI) in the first patient of its FDA-approved clinical study. The participant is a woman from Michigan who lost the ability to speak due to a neurological injury, likely from a stroke or neurodegenerative disease. The device, featuring 1,024 electrodes, is designed to decode neural signals and translate them into text or synthetic speech, offering a communication pathway for people with severe paralysis. This milestone comes after years of development: Paradromics was founded in 2015 by neuroscientist Matt Angle and has raised over $70 million in funding, including a $33 million round in 2021 led by Moore Strategic Ventures. The clinical study, named COMMAND, received FDA approval in 2024 and plans to enroll five participants in total. The surgery was performed at the University of Texas Medical Center in Austin, and the patient is recovering with no reported complications so far.

Why Is This Important?

This milestone positions Paradromics as the most serious rival to Neuralink, Elon Musk's company that has dominated the BCI narrative. While Neuralink has implanted its device in at least three patients, Paradromics demonstrates that a viable alternative exists with a different technical approach. The Connexus stands out for its high electrode density (1,024 channels, similar to Neuralink but with a modular design) and its less invasive implantation method: it uses a set of micro-wires inserted into the motor cortex, without requiring a surgical robot like Neuralink's. Additionally, the device is fully implantable, with an external unit placed behind the ear for data transmission. Competition accelerates innovation and could lead to more accessible therapies for neurological disorders. Historically, BCIs have been limited to academic trials with few electrodes; the leap to high-density systems in humans is an advance comparable to the transition from early pacemakers to modern devices. By authorizing this study, the FDA recognizes the potential of BCIs to restore communication in patients with locked-in syndrome or amyotrophic lateral sclerosis (ALS), conditions for which no effective treatments exist.

Consequences for the Sector

Paradromics' advance pressures Neuralink to demonstrate consistent results and overcome regulatory challenges. Neuralink has faced criticism for lack of transparency in its data and animal incidents, while Paradromics has adopted a more cautious approach, publishing preclinical results in peer-reviewed journals. It also validates the FDA's interest in BCIs as legitimate medical devices. In 2023, the agency issued preliminary guidance for implantable BCIs, and this study is one of the first to follow those guidelines. Other competitors, such as Synchron (whose stentrode is implanted through blood vessels) or Blackrock Neurotech (which has been conducting trials with electrode arrays for years), are expected to intensify their efforts. For investors, the BCI sector is consolidating as a high-potential area: the global BCI market is estimated to reach $5.4 billion by 2030, according to Grand View Research. However, technical and ethical risks persist: device durability, long-term safety, and neural data privacy issues are key challenges. The comparison with Neuralink is inevitable: while Musk promises symbiosis with AI, Paradromics focuses on concrete medical applications, which could give it a regulatory advantage.

What Readers Should Know

• Paradromics' study is still in its early phase; more data on long-term safety and efficacy are needed. The company expects to publish preliminary results in 2026.
• The device does not restore movement, only communication through neural decoding. The patient will be able to control a cursor or generate text by thinking of words, but not walk or move limbs.
• The FDA's approval of this study indicates an evolving regulatory framework for BCIs. The agency classified the device as significant risk, implying close monitoring.
• Compared to Neuralink, Paradromics uses a less publicized but technically solid approach. While Neuralink prioritizes transmission speed and aesthetics, Paradromics focuses on robustness and modularity to facilitate repairs or upgrades.
• The device's cost has not been disclosed, but it is expected to be high initially, though it could decrease with mass production and insurance coverage.

“Paradromics shows there is more than one path to clinically viable brain-computer interfaces,” notes TheVortiq's chief technology analyst. “While Neuralink grabs headlines, Paradromics quietly builds a platform that could be more practical for real medical use. The real competition is not in headlines, but in the efficacy and safety data both generate in the coming years.”